top of page

Media & Press Updates

Visicell technology to be featured at ISEV2020

February 20, 2020

Our collaborators, Drs. Laura Perin and Sargis Sedrakyan from CHLA, will share exciting findings using Visicell technology at this year's ISEV virtual meeting on July 20-22.

Visicell advanced to the semi-final round of San Diego Angel Conference

February 17, 2020

Visicell, along with eleven other companies has been selected as semifinalists at the 2020 San Diego Angel Conference for a chance to win an investment of $200k.

Introducing the Visicell advisory board

November 22, 2019

Visicell had assembled an accomplished advisory board composed of serial entrepreneurs and stakeholders in the cell therapy industry.  An inaugural advisory meeting was held to celebrate this momentous occasion.

Quarter-finalists announced for the 2nd annual San Diego Angel Conference

February 3, 2020

Visicell is one of twenty-seven companies advancing to the quarterfinal round of San Diego Angel Conference from a pool of more than 100 startup companies. The winning company will take home a guaranteed $200,000 investment from angels at the main event on March 28. 

Visicell presents at California Institute of Regenerative Medicine

March 6, 2019

Visicell visited California Institute of Regenerative medicine (CIRM) and presented their recent development on non-invasive cell tracking technology. Learn more about CIRM and its patient-centered mission and impact using the link below.

Visicell is now part of Cell Therapy - TRAcking, Circulation, & Safety (CT-TRACS) Committee at HESI

February 28, 2019

Visicell had recently joined HESI CT-TRACS, a global committee with multiple stakeholders ranging from academic institutions, biotechnology/pharmaceutical companies, regulatory bodies, and other non-profit organizations across Americas, EU, and Asia. Visicell will work closely with other members of the committee such as Novartis, Beringer Manheim, Takeda, GE, Memorial Sloan Kettering, CIRM, and FDA…etc, to develop common best practices and standardize methods for evaluating the safety of cell therapy in patients

The Pitch @ Ignite 2019

February 15, 2019

Visicell had advanced to the semi-finals of The Pitch @ Ignite, UC San Diego’s flagship innovator and entrepreneur conference.

Visicell awarded a grant by StartR Inclusion

November 30, 2018

Visicell is proud recipient of a grant from StartR Inclusion (formerly known as mystartupXX), and is grateful for StartR's continued support. 

NSF I-Corps Program

November 1, 2018

Visicell team members have completed the NSF I-Corps program through the Institute of Global Entrepreneur at University of California San Diego and was awarded NSF Seed Funding for market validation.

Hera Fast Pitch 2017

August 31, 2017

After a very competitive process, Visicell was selected to be among the 12 female-led startups to pitch at Hera Fast Pitch 2017.

Pinnacle Pitch 2017

April 19, 2017

At a pitch event held by Athena in partnership with mystartupXX, an accelerator for women entrepreneurs, Visicell was selected as one of the final 5 contestants.

Visicell awarded 2nd place prize at StartR Demo Day Event

April 13, 2017

Visicell Medical Inc. graduated from the class of Fall 2016 as part of StartR accelerator program at California Institute for Innovation and Development and won second place at the StarR Demo day pitch contest.

Visicell joined mystartupXX Accelerator

January 24, 2017

Visicell joined the mystartupXX program at California Institute for Innovation and Development, an accelerator for women entrepreneurs.

NIH researchers discover new method to label cells for tracking by MRI

March 6, 2012

The genesis of Visicell core technology.

Next entries >>

  • We always have a story to tell, so check our news section often and contact us if you need more information!

Anchor 1
bottom of page